Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 8/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.36 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.36 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.36 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20119408 | 0.86 | ACACB (0.40) | KCNH2TMEM97SIGMAR1MEN1KMT2A | |
| SCHEMBL21882589 | 0.82 | ACACB (0.38) | KCNH2TMEM97SIGMAR1MEN1KMT2A | |
| SCHEMBL21882784 | 0.78 | ACHE (0.31) | KCNH2TMEM97SIGMAR1 | |
| SCHEMBL11540527 | 0.75 | ACACB (0.41) | ACACBTEAD1TEAD4TEAD2TRPV3 | |
| SCHEMBL13180668 | 0.75 | MEN1 (0.63) | KCNH2TMEM97SIGMAR1MEN1KMT2A | |
| SCHEMBL20173789 | 0.73 | KCNH2 (0.37) | KCNH2TMEM97SIGMAR1MEN1KMT2A | |
| SCHEMBL21882783 | 0.73 | DRD2 (0.42) | KMT2AACACBTEAD1TEAD4TEAD2 | |
| SCHEMBL20178642 | 0.73 | NOTUM (0.43) | MEN1KMT2AACACBTEAD1TEAD4 | |
| SCHEMBL21882615 | 0.70 | TMEM97 (0.60) | KCNH2TMEM97SIGMAR1MEN1KMT2A | |
| SCHEMBL21725631 | 0.70 | P2RX7 (0.35) | ACACBMC4RNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | KCNH2 4447/4885TMEM97 192/4885SIGMAR1 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.